News
Current Recommendations by the ELN Expert Panel on AML Diagnosis Management
The 2022 recommendations from European LeukemiaNet (ELN) add new information to the previous recommendations from 2010 and 2017. They concern the diagnosis and treatment of acute myeloid leukemia (AML) in adults from the perspective of pathogenesis, disease classification adjustment, possibilities of genomic diagnosis, and the inclusion of minimal residual disease (MRD) assessment.
Overuse of Corticosteroids as a Serious Problem in ITP
Corticosteroids (CS) are a common part of the treatment for immune thrombocytopenia (ITP). However,…
Romiplostim in Life-Threatening Bleeding Situations − Case Reports
Immune thrombocytopenic purpura, or immune thrombocytopenia (ITP), typically manifests as bleeding…
CYP Enzyme? Cytochrome P450 2D6 and Drug Metabolism
The CYP2D6 isoenzyme of cytochrome P450 participates in the metabolism of approximately 20% of commonly...
Association of M2 Haplotype of the Annexin A5 Gene with Recurrent Reproductive Losses
Annexin A5 (ANXA5) is a placental anticoagulant protein that ensures adequate blood supply to the…
Etiology of Recurrent Reproductive Losses – Focus on Genetics
Repeated pregnancy losses pose a significant threat to a woman's physical and mental health. The…
Li-Fraumeni Syndrome – Indication for Testing and Recommended Surveillance
A germline mutation of the TP53 gene, which causes Li-Fraumeni syndrome, results in a congenital predisposition...
Water Microjet as a Gentler Method of Debridement
Debridement is an integral part of chronic wound treatment. Currently, the most common method is…
Dravet Syndrome – Get to Know It
Dravet syndrome is a severe myoclonic epilepsy occurring in early childhood. It is classified as a…
Popular this week
- Can Dogs Detect Parkinson’s Disease by Smell?
- Specially Designed Video Games May Support Mental Health in Children and Adolescents
- Sarcopenia as a severe organ failure, its diagnosing and present therapeutic possibilities
- COPD and OSA – A Deadly Duo That Raises Five-Year Mortality by One-Third
- Barth Syndrome Has Its First Approved Therapy — For Now Only in the U.S.